SureTrader
Home > Boards > US OTC > Medical - Equipment >

MultiCorp International, Inc. (MCIC)

MCIC RSS Feed
Add MCIC Price Alert      Hide Sticky   Hide Intro
Moderator: sirant, gorbec1, k9narc, MLR_Lite, 4u2nv2
Search This Board:
Last Post: 2/6/2016 12:22:33 AM - Followers: 508 - Board type: Free - Posts Today: 1
ttp://multicorpinternational.com
 

Compass Point Research to Collaborate With NDA Partners to Develop Migraine Combination Drug

 
NASHVILLE, TN, Apr 07, 2015 (Marketwired via COMTEX) -- Lori Nesbitt, PharmD, Chief Executive Officer of Compass Point Research, announced today that the company has entered into an agreement with NDA Partners LLC, a highly regarded medical product development and regulatory strategy consultancy, to collaborate in the development of a new combination drug for the treatment of migraine headaches. Compass Point has been retained by the drug sponsor, MultiCorp International, Inc., a publicly traded company located in Sun Valley, CA, to manage the product development program, and NDA Partners will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a preIND meeting with the FDA review division.

The product is a combination of two currently FDA approved drugs, diphenhydramine (Benadryl(R)) and trimethobenzamide (Tebamide(R), Tigan(R)), both of which can be delivered in an oral dosage form. Diphenhydramine is used clinically in combination with other dopamine antagonists such as prochloperazine and metoclopramide as first line therapy to treat migraine headaches. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting. In an emergency department-based clinical study conducted in 2005, the drug combination, delivered as a single injection intramuscularly, demonstrated pain relief, tolerability, and efficacy at 24 hours compared to subcutaneous sumatriptan.

NDA Partners has assembled a highly experienced product development team with comprehensive expertise that includes regulatory strategy, nonclinical development, toxicology, CMC, clinical pharmacology, and experience in demonstration of clinical effectiveness of new migraine treatments. The team will be led by Charles Grudzinskas, PhD, a Partner in the firm who has led efforts to develop and register dozens of new medical products, and includes David Feigal, MD, former Director, FDA Center for Devices & Radiological Health (CDRH); Jeanine Kuczik, a Partner in NDA Partners with significant experience in the development of migraine treatments; and Anthony DiSanto, PhD, former Vice President of Worldwide Drug Delivery Research & Development for the Upjohn Company.

"We are very pleased to be able to combine our extensive drug development and operational experience with world class development and regulatory experts from NDA Partners," said Dr. Nesbitt. "Together, we will deliver an outstanding solution for our client."

NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include two former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 60 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.

MultiCorp International, Inc. (Sun Valley, CA) is a diversified company that operates in various business sectors including property development, constructions, medical, and hospitality as well as commodities such as oil and gas, and entertainment. The vision of management for the company is to diversify into many fields wherein management's expertise, along with its strategic partner's experience, will enable it to participate in high growth markets and increase profitability.

"This is an important program for us, and we believe we have a potential break-through product under development that can provide longer-lasting relief for those suffering from migraine headaches," said Ben Friedman, Rph and President of MultiCorp International, Inc. "Compass Point has assembled an outstanding team to help us develop this product, and we look forward to working with them to fill this important medical need."

About Compass Point Research

Compass Point Research is a full-service clinical and translational research management and consulting firm. The company's focus is on facilitating all aspects of clinical trials operations for community-based healthcare providers, including drug, device, nutritional supplement and consumer product development from discovery through clinical studies, and post-approval support. In addition, Compass Point develops and coordinates multi-center outcomes and registry trials for industry sponsors, healthcare providers and payers, delivering scientifically rigorous research outcomes in an affordable environment. The company has been able to assist providers with not only eliminating a subsidy for research, but actually realizing a net profit for the department or cost center while adhering to all governing regulations and internal standard operating procedures.

       Contact Lori A. Nesbitt, PharmD, MBA Chief Executive Officer Office: 615-522-5424 Mobile: 615-418-8987 Fax: 615-522-5401 Email: lnesbitt@compasspointresearch.com    

SOURCE: Compass Point Research

         

(C) 2015 Marketwire L.P. All rights reserved.

 


Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication

 

Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication

Company Seeking Clinical Trial Partner to Begin Testing in First Quarter of 2014

SUN VALLEY, CA--(Marketwired - Dec 17, 2013) - MultiCorp International, Inc, (OTC Pink: MCIC) has acquired a 70% stake in a patented migraine medication. The company released the following statement:

"MultiCorp International, Inc has acquired a 70% ownership in a patented migraine medicine that has shown to aid in the symptoms of migraine headaches. According to www.migraine.com in the U.S. alone more than 37 million people suffer from migraines and globally over 330 million people have migraines on a constant basis. The medication was developed by a physician that MultiCorp will work closely with in order to gain FDA approval for the medication. The company plans to begin clinical trials in the first quarter of 2014 and hope to have the medication to market as soon as possible. The information on the patent can be found at http://www.faqs.org/patents/app/20090018205. Under the terms of the agreement, MultiCorp will have full authority to oversee the clinical trials of the product, marketing and selling of the medication, as well the overall business of getting the product to market as quickly as possible and retaining a 70% interest in the product. With the average cost of $145 per month in medication for migraine sufferers, the market for this product is exponential here in the U.S. and globally."

For companies wishing to assist MultiCorp in clinical trials, please email us at info@multicorpinternational.com

 

 

 

Management

 



Ben Friedman - President
Mr. Friedman has worked in the medical and pharmacology business for over 35 years. A licensed pharmacist, Mr. Friedman has overseen developing several proprietary prescription compounds and several OTC medications throughout his career. In addition, Ben owned hotels and other properties he's developed. Ben also has been working in the capital markets since 2005 wherein his financial acumen has helped companies raise in excess of $15 million in private funding. Mr. Friedman currently holds a BA in business and is currently licensed to practice pharmacy in California and hold his board certification in pharmacology


 






 



 


 



 

AS info DE. Dept. of Corp. 

24/7 Phone: 302-739-3073, press #8 file number 3866564
http://www.corp.delaware.gov/default.shtml
Note: Web site does not give the AS. Must call, automated 24/7, or during business hours if one wishes to speak in person. 

Company Information

 MultiCorp International, Inc
10771 Sherman Way
Sun Valley, CA 91352
Phone: (818) 255-2476
Fax: (818) 255-2122

 Transfer Agent

Signature Stock Transfer, Inc.

2632 Coachlight Ct.
Plano, TX75093
Phone972-612-4120 Fax972-612-4122

Email - signaturestocktransfer@msn.com

      

 

This board is for discussing XMDC.
Information posted either positive or negative is accepted.
Personal attacks, repetitive, off topic posts or outright flame baiting posts are not accepted.
Posts that respond to PM (One way messages) are not allowed. Vulgarity is not acceptable. Violation of ones privacy is not acceptable.

Posts in violation of the rules will be deleted. Repeat offenders will be reported to the admins of IHUB.


Rules of the board per IHUB:
http://www.investorshub.com/boards/complex_terms.asp
 

 
Share structure

As of 06/18/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/01/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/03/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/14/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/16/08: 31,237,031 shares outstanding: 24,203,809 shares free trading: 7,033,562 shares restricted
As of 07/23/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/06/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/13/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/22/08: 86,737,031 shares outstanding: 80,057,796 shares free trading: 6,679,235 shares restricted; 1,000,000,000 shares Authorized.
As of 08/25/08: 101,737,031 shares outstanding: 95,057,796 shares free trading: 6,679,235 shares restricted; 1,000,000,000 shares Authorized.
As of 09/02/08: 245,737,031 shares outstanding: 239,489,809 shares free trading: 6,247,222 shares restricted; 1,000,000,000 shares Authorized.
As of 07/21/09: 256,737,031 shares outstanding: 239,065,599 shares free trading: 17,671,432 shares restricted; 1,000,000,000 shares Authorized.
As of 09/22/09: 256,737,031 shares outstanding: 239,065,599 shares free trading: 17,671,432 shares restricted; 1,000,000,000 shares Authorized.
As of 10/05/09: 616,737,031 shares outstanding: 299,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 10/05/09: 616,737,031 shares outstanding: 299,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 10/27/09: 636,737,031 shares outstanding: 319,497,611 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/04/09: 649,737,031 shares outstanding: 332,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/09/09: 766,487,031 shares outstanding: 351,681,600 shares free trading: 414,805,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/18/09: 770,487,031 shares outstanding: 355,681,600 shares free trading: 414,805,431 shares restricted; 1,000,000,000 shares Authorized.
As of 12/03/09: 783,137,031 shares outstanding: 370,891,600 shares free trading: 412,245,431 shares restricted; 1,000,000,000 shares Authorized.
As of 12/10/09: 986,490,863 shares outstanding: 378,391,600 shares free trading: 608,099,263 shares restricted; 1,000,000,000 shares Authorized.
As of 02/01/10: 986,490,863 shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,000,000,000 shares Authorized.
As of 02/12/10: 986,490,863 shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,000,000,000 shares Authorized.
As of 10/17/10: 986,490,863  shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,750,000,000 shares Authorized.
As of 12/31/11  1,384,887,031 shares outstanding:462,855,646 shares free trading: 922,031,385 shares restricted:1,750,000,000 shares Authorized.
As of 08/30/12  984,887,031 shares outstanding: : 462,885,646 Free Trading : 1,750,000,000 shares Authorized.

 

SHAREHOLDERS' EQUITY, Per Company Balanced sheet
As of Sept 30, 2012 the company has 1,392,887,031
shares of common stock issued and outstanding.


 


 

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MCIC
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#186928  Sticky Note SUN VALLEY, CA, Jan 21, 2016 (Marketwired via MLR_Lite 01/21/16 12:51:41 PM
#185545  Sticky Note Compass Point Research to Collaborate With NDA Partners 4u2nv2 04/07/15 09:42:53 PM
#187110   How come there isn't a countdown clock for DKLN 02/06/16 12:22:33 AM
#187107   Important update is coming soon per the website. MLR_Lite 02/05/16 11:45:04 PM
#187106   maybe thats why ceo spot up gorbec1 02/05/16 09:44:57 PM
#187105   best update would be a merger news with DHANA 02/05/16 09:15:57 PM
#187104   thanks cant wait to see gorbec1 02/05/16 08:57:52 PM
#187103   Wow important update coming soon per the website. sirant 02/05/16 08:27:28 PM
#187102   and im using it as a whisky flask gorbec1 02/05/16 07:10:04 PM
#187101   Remember that time that I sold one of 4u2nv2 02/05/16 05:02:43 PM
#187099   Yes 4u, always good to see/hear from you Bubba714 02/05/16 04:33:51 PM
#187098   Yea. For sure. 4u2nv2 02/05/16 04:06:54 PM
#187097   well still up from the week gorbec1 02/05/16 04:03:53 PM
#187096   Nice to hear from you Bubba. I always 4u2nv2 02/05/16 03:49:44 PM
#187095   It would be nice if we had another Bubba714 02/05/16 03:43:17 PM
#187094   I agree. Level 2 says all systems go 4u2nv2 02/05/16 03:13:22 PM
#187093   Strong buy at the end of day yesterday PEACHMAN 02/05/16 01:51:40 PM
#187092   Buckle in going to be a good ride. sirant 02/05/16 12:22:55 PM
#187091   grabbed some. its been moving.......................... gail 02/05/16 12:14:32 PM
#187090   I see the pathetic volume. Around $1500 DKLN 02/05/16 12:05:32 PM
#187089   The best part is level 2 is very sirant 02/05/16 11:56:04 AM
#187088   Hey! Check out the putrid volume and MLR_Lite 02/05/16 11:54:32 AM
#187087   Sure is going up fast. 4u2nv2 02/05/16 11:43:05 AM
#187086   MCIC On The Move, Up 28% This Morning, Mark280z 02/05/16 11:42:10 AM
#187085   .0022x.0023 GO MCIC $ $ $ $ $ sirant 02/05/16 10:42:55 AM
#187084   Yep looking good. Back over .002. GO MCIC $ sirant 02/05/16 10:33:22 AM
#187083   little buying going on and gorbec1 02/05/16 10:25:19 AM
#187082   Good Morning Everyone Yes very happy to get sirant 02/05/16 09:43:50 AM
#187081   lol money is money gorbec1 02/05/16 09:25:38 AM
#187080   You are probably correct. I look forward MLR_Lite 02/05/16 09:18:17 AM
#187079   I don't believe those were day traders.... jonblair77 02/05/16 08:48:42 AM
#187078   A million dollars? That is what I MLR_Lite 02/05/16 08:42:53 AM
#187077   yes it does hope gorbec1 02/05/16 08:32:27 AM
#187076   Howdy. Been a nice week here. MLR_Lite 02/05/16 07:44:39 AM
#187075   morning mcic ers gorbec1 02/05/16 07:43:10 AM
#187074   i have to say that was gorbec1 02/04/16 07:58:15 PM
#187072   Yea. 1.75 million trade just before the close 4u2nv2 02/04/16 07:53:00 PM
#187071   I love a good end of day ask jmgotch 02/04/16 05:36:21 PM
#187070   Need to decide the line that will be MLR_Lite 02/04/16 05:29:29 PM
#187069   Exactly. Unless/until Lisenby (no need for the Mr.) DKLN 02/04/16 05:24:45 PM
#187068   $5000 in shares traded is supposed to be DKLN 02/04/16 05:17:17 PM
#187067   lol dont forget only about 5000.00 gorbec1 02/04/16 05:03:31 PM
#187066   Don't forget that it is putrid volume and MLR_Lite 02/04/16 05:01:20 PM
#187065   wow 1.7 mil last 10 min of trading gorbec1 02/04/16 04:22:34 PM
#187064   yep looking good gorbec1 02/04/16 03:48:33 PM
#187063   Not a bad day .0017x.0018 down 5.3% GO MCIC sirant 02/04/16 03:44:46 PM
#187062   Next update coming... Three years from now that is aaronious 02/04/16 01:48:43 PM
#187061   You are the best, thank you, iou . dubc 02/04/16 11:07:48 AM
#187060   Still the same .0013x.0018 2.1 million on the sirant 02/04/16 10:49:29 AM
#187059   Hows the bid and ask numbers ? Is dubc 02/04/16 10:32:10 AM
#187058   Obvious up trend . . Churning . . dubc 02/04/16 10:22:02 AM
#187057   well a 1/4 of it gorbec1 02/04/16 09:43:49 AM
PostSubject